Three teams of USC stem cell researchers have won a coveted prize — the opportunity to test 3,000 drug candidates or chemicals for the potential to help patients. Two teams will focus their efforts on cancer; the third will search for ways to accelerate the healing of large bone fractures.
The free screens will take place at the Choi Family Therapeutic Screening Facility, part of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. Andrew McMahon, director of the stem cell research center, is sponsoring the bone repair project, and Stephen Gruber, director of
One in 10 adults in the U.S. — more than 20 million people — are suffering from some degree of chronic kidney disease. Kidney transplants offer a hope for cure, but thousands of patients die each year due to a shortage of donor organs. Even patients who are lucky enough to receive transplants run the risk of their immune systems rejecting the donor kidneys, and they have to take immunosuppressive drugs with serious side effects for the rest of their lives.
Vito Campese, professor and chair of the Keck School of Medicine of USC’s nephrology division, underscores the need to
Piece by missing piece, scientists at the Keck School of Medicine of USC are deciphering the powerful gene regulatory circuit that maintains and controls the potential of embryonic stem cells (ESCs) to form any type of cell in the body.
Recent findings by Provost Professor Andrew McMahon, director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, and Qilong Ying, associate professor of cell and neurobiology, underscore the essential role of basic science in paving the way for future medical breakthroughs.
McMahon and Ying are in pursuit of the ways in which the intricate